The dire need to develop a clinically validated screening method for the detection of early-stage ovarian cancer

Biomarkers in Medicine

Volumn 4, Issue 3, 2010, Pages 437-439

  Dutta, Sonia ^a   Wang, Feng Qiang ^a   Fishman, David A ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; BRCA1 PROTEIN; BRCA2 PROTEIN; CA 125 ANTIGEN; CLAUDIN; CONTRAST MEDIUM; GENE PRODUCT; HUMAN EPIDIDYMAL PROTEIN 4; KALLIKREIN; LYSOPHOSPHATIDIC ACID; MICRORNA; OSTEOPONTIN; UNCLASSIFIED DRUG;

BENIGN TUMOR; CANCER SCREENING; CANCER STAGING; CANCER SURVIVAL; CLINICAL PROTOCOL; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; EARLY DIAGNOSIS; EDITORIAL; FEMALE; HIGH RISK POPULATION; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALIGNANT NEOPLASTIC DISEASE; MEDICAL TECHNOLOGY; NEOVASCULARIZATION (PATHOLOGY); NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY CANCER; OVARY TUMOR; POSTMENOPAUSE; SCREENING TEST; TRANSVAGINAL ECHOGRAPHY; WOMEN'S HEALTH; WORLD HEALTH ORGANIZATION;

BIOLOGICAL MARKERS; CLAUDINS; EARLY DETECTION OF CANCER; EPIDIDYMAL SECRETORY PROTEINS; FEMALE; HUMANS; KALLIKREINS; LYSOPHOSPHOLIPIDS; NEOPLASM STAGING; OSTEOPONTIN; OVARIAN NEOPLASMS;

EID: 77953794844     PISSN: 17520363     EISSN: None     Source Type: Journal    
DOI: 10.2217/bmm.10.54     Document Type: Editorial

References (13)

1. Wilson JM, Jungner YG: Principles and practice of mass screening for disease. Bol. Oficina Sanit. Panam. 65(4), 281-393 (1968) [In Spanish].
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ: Cancer statistics, 2009. CA Cancer J. Clin. 59(4), 225-249 (2009).
3. Xu Y, Shen Z, Wiper DW et al.: Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers. JAMA 280(8), 719-723 (1998).
4. Hellstrom I, Raycraft J, Hayden-Ledbetter M et al.: The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res. 63(13), 3695-3700 (2003).
5. Huhtinen K, Suvitie P, Hiissa J et al.: Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts. Br. J. Cancer 100(8), 1315-1319 (2009).
6. Nakae M, Iwamoto I, Fujino T et al.: Preoperative plasma osteopontin level as a biomarker complementary to carbohydrate antigen 125 in predicting ovarian cancer. J. Obstet. Gynaecol. Res. 32(3), 309-314 (2006).
7. Kim K, Visintin I, Alvero AB, Mor G: Development and validation of a protein-based signature for the detection of ovarian cancer. Clin. Lab. Med. 29(1), 47-55 (2009).
8. White NM, Mathews M, Yousef GM et al.: Human kallikrein related peptidases 6 and 13 in combination with CA125 is a more sensitive test for ovarian cancer than CA125 alone. Cancer Biomark. 5(6), 279-287 (2009).
9. Gogoi R, Srinivasan S, Fishman DA: Progress in biomarker discovery for diagnostic testing in epithelial ovarian cancer. Expert Rev. Mol. Diagn. 6(4), 627-637 (2006).
10. Szab I, Kiss A, Schaff Z, Sobel G: Claudins as diagnostic and prognostic markers in gynecological cancer. Histol. Histopathol. 24(12), 1607-1615 (2009).
11. Taylor DD, Gercel-Taylor C, Parker LP: Patient-derived tumor-reactive antibodies as diagnostic markers for ovarian cancer. Gynecol. Oncol. 115(1), 112-120 (2009).
12. Kwon JS, Daniels MS, Sun CC, Lu KH: Preventing future cancers by testing women with ovarian cancer for BRCA mutations. J. Clin. Oncol. 28(4), 675-682 (2010).
13. Fleischer AC, Lyshchik A, Jones HW 3rd et al.: Diagnostic parameters to differentiate benign from malignant ovarian masses with contrast-enhanced transvaginal sonography. J. Ultrasound Med. 28(10), 1273-1280 (2009).